Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 1:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: cabazitaxel Clear all
Terminated Phase 2 Interventional

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

NCT01469338
View directory record Official record
Conditions
Diarrhea, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
cabazitaxel, prednisone, octreotide pamoate, questionnaire administration, octreotide acetate
Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 23, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy

NCT01437488
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Cabazitaxel, Neulasta, CT Scan, Blood Draw
Drug · Procedure · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Bethesda, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 23, 2026, 1:00 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

NCT01335204
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Cabazitaxel plus bavituximab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 23, 2026, 1:00 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 23, 2026, 1:00 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

NCT02522715
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
Interventions
Cabazitaxel, Enzalutamide, Laboratory Biomarker Analysis, Pharmacological Study, Prednisone
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
3
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 1:00 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

NCT01001221
View directory record Official record
Conditions
Neoplasms, Malignant
Interventions
cabazitaxel, gemcitabine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Detroit, Michigan • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Sep 23, 2026, 1:00 AM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 23, 2026, 1:00 AM EDT
Recruiting Phase 2 Interventional

Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

NCT06738303
View directory record Official record
Conditions
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Cabazitaxel and carboplatin, Lu-PSMA-617
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 23, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

NCT03934840
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Chicago, Illinois • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 23, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

NCT03556904
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ablative Radiation Therapy, Hormone therapy or chemotherapy
Radiation · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 23, 2026, 1:00 AM EDT
Active, not recruiting Phase 2 Interventional

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

NCT04592237
View directory record Official record
Conditions
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
Cabazitaxel, Carboplatin, Cetrelimab, Niraparib
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 23, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

NCT02985957
View directory record Official record
Conditions
Prostate Cancer
Interventions
Nivolumab, Ipilimumab, Cabazitaxel, Prednisone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
15
States / cities
Tucson, Arizona • Marietta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 23, 2026, 1:00 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

NCT04709276
View directory record Official record
Conditions
Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer
Interventions
Nivolumab, Ipilimumab, Carboplatin, Cabazitaxel
Drug
Lead sponsor
Andrew J. Armstrong, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 23, 2026, 1:00 AM EDT
Terminated Phase 2 Interventional Results available

Cabazitaxel and Radiation For Patients With Prostate Cancer

NCT01650285
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 23, 2026, 1:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

NCT01751308
View directory record Official record
Conditions
Malignant Solid Tumor - Malignant Nervous System Neoplasm
Interventions
Cabazitaxel (XRP6258)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 18 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Sep 23, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

NCT03248570
View directory record Official record
Conditions
Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
Interventions
Pembrolizumab, Chemotherapy
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 23, 2026, 1:00 AM EDT
Completed Phase 1 Interventional

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer

NCT01594918
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Cabazitaxel, Mitoxantrone, Prednisone, Pegfilgrastim
Drug
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • San Francisco, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 23, 2026, 1:00 AM EDT
Withdrawn Phase 1 Interventional

Phase I Trial of PACE for Metastatic Prostate Cancer

NCT03110588
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
PACE with Cabazitaxel (15 mg/m2), PACE with Cabazitaxel (20 mg/m2)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 23, 2026, 1:00 AM EDT
Completed No phase listed Observational

Multi-academic Center Study of Xofigo Patients

NCT03419442
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant
Interventions
Xofigo, Taxotere, Jevtana
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 23, 2026, 1:00 AM EDT
Completed Phase 2 Interventional Results available

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

NCT04495179
View directory record Official record
Conditions
Progressive Metastatic Castrate-Resistant Prostate Cancer
Interventions
AZD4635, Durvalumab, Cabazitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Sacramento, California • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 23, 2026, 1:00 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

NCT06085729
View directory record Official record
Conditions
Prostate Cancer
Interventions
ADI-PEG 20, Cabazitaxel, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 23, 2026, 1:00 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

NCT02202772
View directory record Official record
Conditions
Urothelial Carcinoma of the Urinary Bladder
Interventions
Cabazitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
Guarionex J. Decastro
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 23, 2026, 1:00 AM EDT
Completed Phase 3 Interventional Results available

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

NCT01308567
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel (XRP6258), Docetaxel (XRP6976), Prednisone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
32
States / cities
Muscle Shoals, Alabama • Anaheim, California • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 23, 2026, 1:00 AM EDT
Terminated Phase 2 Interventional Results available

Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer

NCT01845792
View directory record Official record
Conditions
Prostate Cancer
Interventions
Cabazitaxel with Abiraterone Acetate, Cabazitaxel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 95 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 23, 2026, 1:00 AM EDT